HilleVax, Inc.: restructuring charge — HilleVax cuts 15 employees (25% of workforce) to reduce costs; exploring strategic alternatives

HilleVax, Inc.

Workforce reduction of approximately 15 employees (~25% of total workforce).
Estimated charges of ~$1.3M for severance, benefits and termination costs, expected in Q4 2024.
Company exploring continued development of norovirus vaccine candidates and business development/strategic alternatives.
Action aims to reduce operating expenses amid uncertainty over lead candidate HIL-214.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

HilleVax, Inc. announced a restructuring with charges of approximately $1.3 million (approximately 15 employees, constituting approximately 25% of the Company's workforce).

Type: restructuring
Charge: approximately $1.3 million
Headcount: approximately 15 employees, constituting approximately 25% of the Company's workforce

Exact text from the filing

these vaccine candidates and other strategic alternatives. The Company currently estimates that it will incur charges associated with the workforce reduction of approximately $1.3 million primarily related to employee severance payments, benefits and related termination costs. The Company expects that the reduction in force will be substantially complete with the

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0000950170-24-115027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.